Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
8 "Ji-Yeon Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Breast cancer
Impact of Social Support during Diagnosis and Treatment on Disease Progression in Young Patients with Breast Cancer: A Prospective Cohort Study
Danbee Kang, Seri Park, Hyo Jung Kim, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Se Kyung Lee, Ji-Yeon Kim, Seok Jin Nam, Juhee Cho, Yeon Hee Park
Cancer Res Treat. 2024;56(1):125-133.   Published online September 4, 2023
DOI: https://doi.org/10.4143/crt.2023.673
AbstractAbstract PDFPubReaderePub
Purpose
We evaluated the association between changes in social support after cancer treatment and recurrence-free survival (RFS) in such patients using a prospective cohort study.
Materials and Methods
Data were obtained from a prospective cohort study (NCT03131089) conducted at Samsung Medical Center (2013-2021). The primary outcome measure was RFS. Social support was measured using the social and family well-being (SFWB) domain of the Functional Assessment of Cancer Therapy-General. We calculated the changes in SFWB scores before and during treatment and the hazard ratio for RFS by comparing such changes.
Results
The mean±standard deviation (SD) age of the patients was 35±3.9 years, and 71.5% and 64.8% of the patients were married and had children, respectively. The mean±SD SFWB score at baseline was 20.5±5.0 out of 26. After cancer treatment, 35.9%, 10.3%, and 53.8% of the participants had increasing, unchanged, and decreasing SFWB scores, respectively. The decreasing SFWB score group had a higher risk of mortality or recurrence than the increasing group. Risk factors for the decreasing score were the presence of children during diagnosis.
Conclusion
In this cohort, changes in social support after treatment were associated with RFS in young patients with breast cancer. Health professionals should develop family interventions to help them receive proper social support.
  • 3,292 View
  • 208 Download
Close layer
General
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
Young-Woong Won, Jin-Hyoung Kang, Jung Hye Kwon, Dong-Hoe Koo, Jung Hun Kang, Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Dae-Won Lee, Joohyuk Sohn, So Yeon Oh, Kyung Hee Lee, Su-Jin Koh, Keun Seok Lee, Chan-Kyu Kim, Ji-Yeon Kim, Jun Ho Ji, Sung-Bae Kim, Joo Young Ha, Ho Young Kim
Cancer Res Treat. 2023;55(4):1096-1103.   Published online April 7, 2023
DOI: https://doi.org/10.4143/crt.2022.1565
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient data on ethanol-induced symptoms when docetaxel-containing ethanol is administered. The primary purpose of this study was to investigate the frequency and pattern of ethanol-induced symptoms during and after docetaxel administration. The secondary purpose was to explore the risk factors for ethanol-induced symptoms.
Materials and Methods
This was a prospective, multicenter, observational study. The participants filled out ethanol-induced symptom questionnaire on the day of chemotherapy and the following day.
Results
Data from 451 patients were analyzed. The overall occurrence rate of ethanol-induced symptoms was 44.3% (200/451 patients). The occurrence rate of facial flushing was highest at 19.7% (89/451 patients), followed by nausea in 18.2% (82/451 patients), and dizziness in 17.5% (79/451 patients). Although infrequent, unsteady walking and impaired balance occurred in 4.2% and 3.3% of patients, respectively. Female sex, presence of underlying disease, younger age, docetaxel dose, and docetaxel-containing ethanol amount were significantly associated with the occurrence of ethanol-induced symptoms.
Conclusion
The occurrence of ethanol-induced symptoms was not low in patients receiving docetaxel-containing ethanol. Physicians need to pay more attention to the occurrence of ethanol-induced symptoms and prescribe ethanol-free or low-ethanol-containing formulations to high-risk patients.

Citations

Citations to this article as recorded by  
  • Evaluation of self-assembling properties of paclitaxel-biotin conjugates
    Dmitry V. Beigulenko, Anna Yu. Belyaeva, Ekaterina S. Kazakova, Maria M. Antonova, Aleksander S. Peregudov, Aleksey A. Nikitin, Tatyana S. Kovshova, Yulia V. Ermolenko, Konstantin A. Kochetkov
    Nano-Structures & Nano-Objects.2024; 40: 101375.     CrossRef
  • 3,558 View
  • 218 Download
  • 1 Crossref
Close layer
Breast cancer
Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
Yong-Pyo Lee, Min-Sang Lee, HongSik Kim, Ji-Yeon Kim, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2022;54(4):1130-1137.   Published online January 17, 2022
DOI: https://doi.org/10.4143/crt.2021.1103
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Trastuzumab has markedly improved the survival outcomes of patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer, and dual blockade of HER2 using trastuzumab and pertuzumab in combination with taxanes (THP) has become a standard of care for HER2-positive metastatic breast cancer (MBC) worldwide since the CLEOPATRA trial. We assessed the outcomes of THP as a first-line treatment for Korean HER2-positive MBC patients in the real-world setting.
Materials and Methods
Between August 2008 and October 2020, we identified 228 HER2-positive MBC patients who received THP as a first-line palliative chemotherapy. We analyzed survival outcomes, efficacy, and adverse events of THP retrospectively.
Results
After a median follow-up duration of 28.7 months, median overall survival and progression-free survival were 58.3 months (95% confidence interval [CI], 36.6 to 80.0) and 19.1 months (95% CI, 16.2 to 21.9), respectively. Better survival outcomes were observed in patient who received docetaxel for more than six cycles. Patients exposed to anti-HER2 directed therapies in a perioperative setting had poor survival outcomes. The overall response rate was 86.8% with a complete response (CR) rate of 17.7%. Among responders, 16.7% of patients sustained THP over 35 months and showed better survivals and higher CR rates. Adverse events were comparable to those reported in previous studies.
Conclusion
In a real-world context, clinical outcomes of Korean HER2-positive MBC patients treated with THP were similar to those of patients in the CLEOPATRA trial. Much longer follow-up results would be warranted.

Citations

Citations to this article as recorded by  
  • Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
    Kelvin KH. Bao, Jeffrey CH. Chan, Jocelyn G. Chan, Leone Sutanto, Ka Man Cheung, Harry HY. Yiu
    The Breast.2024; 73: 103612.     CrossRef
  • Bilateral inflammatory recurrence of HER-2 positive breast cancer: a unique case report and literature review
    Rong Qin, Xiangyang Wang, Tingting Fan, Ting Wu, Chao Lu, Xun Shao, Liang Yin
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Biosensing chips for cancer diagnosis and treatment: a new wave towards clinical innovation
    Muhammad Javed Iqbal, Zeeshan Javed, Jesús Herrera-Bravo, Haleema Sadia, Faiza Anum, Shahid Raza, Arifa Tahir, Muhammad Naeem Shahwani, Javad Sharifi-Rad, Daniela Calina, William C. Cho
    Cancer Cell International.2022;[Epub]     CrossRef
  • 6,637 View
  • 312 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
Ji-Yeon Kim, Seok Jin Nam, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Jin Seok Ahn, Young-Hyuck Im, Seok Won Kim, Yeon Hee Park
Cancer Res Treat. 2022;54(4):1091-1098.   Published online January 10, 2022
DOI: https://doi.org/10.4143/crt.2021.901
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) regimen is frequently used to treat early and locally advanced human epidermal growth factor receptor 2 (HER2)–positive breast cancer (BC) in neoadjuvant setting. However, large-scaled real-world evidence did not exist.
Materials and Methods
We retrospectively reviewed medical records of patients with early or locally advanced HER2-positive BC who underwent neoadjuvant TCHP followed by curative surgery at Samsung Medical Center between January 2016 and August 2020.
Results
Of 447 patients, 316 (70.7%) received breast-conserving surgery and 131 (29.3%) received total mastectomy. In terms of neoadjuvant chemotherapy response, pathologic complete response (pCR) and residual cancer burden (RCB) score were analyzed. The rate of pCR was 64% a class of RCB 0 was observed in 65% of cases, RCB class I in 12%, RCB class II in 14%, and RCB class III in 2%. The 3-year event-free survival rate was 90.6%, BC with pCR occurred in 92.8%, and BC with non-pCR in 86.3% (p=0.016). In terms of distant metastasis, the 3-year distant recurrence-free survival rate was 93.5%; BC with pCR occurred in 95.9% and BC with non-pCR in 89.2% (p=0.013). Mucositis (85.2%), pain (83.2%), and diarrhea (70.5%) were the most common non-hematologic adverse events. In terms of hematologic adverse events, anemia (89.9%) was the most commonly observed adverse events followed by thrombocytopenia (29.8%).
Conclusion
Neoadjuvant TCHP therapy had a pCR rate of 64% and a 3-year event-free survival of 90% in real world experience. In terms of toxicity profile, anemia was frequently observed and adequate management including occasional transfusion was required.

Citations

Citations to this article as recorded by  
  • De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China
    Song Wu, Li Bian, Haibo Wang, Shaohua Zhang, Tao Wang, Zhigang Yu, Jianbin Li, Feng Li, Kun Wang, Zefei Jiang
    World Journal of Surgical Oncology.2024;[Epub]     CrossRef
  • Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy
    Haizhu Chen, Xiujuan Gui, Ziwei Zhou, Fengxi Su, Chang Gong, Shunrong Li, Wei Wu, Nanyan Rao, Qiang Liu, Herui Yao
    The Breast.2024; 75: 103733.     CrossRef
  • Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
    Ahmet Bilici, Omer Fatih Olmez, Muhammed Ali Kaplan, Berna Oksuzoglu, Ahmet Sezer, Nuri Karadurmus, Erdem Cubukcu, Mehmet Ali Nahit Sendur, Sercan Aksoy, Dilek Erdem, Gul Basaran, Burcu Cakar, Abdallah T. M. Shbair, Cagatay Arslan, Ahmet Taner Sumbul, Sem
    Acta Oncologica.2023; 62(4): 381.     CrossRef
  • Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials
    Faizan Fazal, Muhammad Nauman Bashir, Maham Leeza Adil, Usama Tanveer, Mansoor Ahmed, Taha Zahid Chaudhry, Ali Ahmad Ijaz, Muhammad Haider
    Cureus.2023;[Epub]     CrossRef
  • Trends of axillary surgery in breast cancer patients with axillary lymph node metastasis: a comprehensive single-center retrospective study
    Yeon Jin Kim, Hye Jin Kim, Soo Yeon Chung, Se Kyung Lee, Byung Joo Chae, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Jai Min Ryu
    Annals of Surgical Treatment and Research.2023; 105(1): 10.     CrossRef
  • Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
    Inês Soares de Pinho, Paulo Luz, Lucy Alves, Raquel Lopes-Brás, Vanessa Patel, Miguel Esperança-Martins, Lisa Gonçalves, Ritas Freitas, Diana Simão, Maria Roldán Galnares, Isabel Fernandes, Silvia Artacho Criado, Salvador Gamez Casado, Jose Baena Cañada,
    Clinical Drug Investigation.2023; 43(9): 691.     CrossRef
  • Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer
    Nalee Kim, Ji-Yeon Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Sei Kyung Lee, Jai-Min Ryu, Yeon Hee Park, Haeyoung Kim
    The Breast.2023; 72: 103594.     CrossRef
  • Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer
    Hee Kyung Ahn, Sung Hoon Sim, Koung Jin Suh, Min Hwan Kim, Jae Ho Jeong, Ji-Yeon Kim, Dae-Won Lee, Jin-Hee Ahn, Heejung Chae, Kyung-Hun Lee, Jee Hyun Kim, Keun Seok Lee, Joo Hyuk Sohn, Yoon-La Choi, Seock-Ah Im, Kyung Hae Jung, Yeon Hee Park
    JAMA Oncology.2022; 8(9): 1271.     CrossRef
  • 7,938 View
  • 591 Download
  • 9 Web of Science
  • 8 Crossref
Close layer
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance
Hee Kyung Kim, Kyung Hee Park, Youjin Kim, Song Ee Park, Han Sang Lee, Sung Won Lim, Jang Ho Cho, Ji-Yeon Kim, Jeong Eon Lee, Jin Seok Ahn, Young-Hyuck Im, Jong Han Yu, Yeon Hee Park
Cancer Res Treat. 2019;51(2):737-747.   Published online September 5, 2018
DOI: https://doi.org/10.4143/crt.2018.342
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to analyze the discordance between immunohistochemistry (IHC)-based surrogate subtyping and PAM50 intrinsic subtypes and to assess overall survival (OS) according to discordance.
Materials and Methods
A total of 607 patients were analyzed. Hormone receptor (HR) expression was evaluated by IHC, and human epidermal growth factor receptor 2 (HER2) expression was analyzed by IHC and/or fluorescence in situ hybridization. PAM50 intrinsic subtypes were determined according to 50 cancer genes using the NanoString nCounter Analysis System. We matched concordant tumor as luminal A and HR+/HER2–, luminal B and HR+/HER2+, HR–/HER2+ and HER2–enriched, and triple-negative breast cancer (TNBC) and normal- or basal-like. We used Ion Ampliseq Cancer Panel v2 was used to identify the genomic alteration related with discordance. The Kaplan-Meier method was used to estimate OS.
Results
In total, 233 patients (38.4%) were discordant between IHC-based subtype and PAM50 intrinsic subtype. Using targeted sequencing, we detected somatic mutation–related discordant breast cancer including the VHL gene in the HR+/HER2– group (31% in concordant group, 0% in discordant group, p=0.03) and the IDH and RET genes (7% vs. 12%, p=0.02 and 0% vs. 25%, p=0.02, respectively) in the TNBC group. Among the luminal A/B patients with a discordant result had significantly worse OS (median OS, 73.6 months vs. not reached; p < 0.001), and among the patients with HR positivity, the basal-like group as determined by PAM50 showed significantly inferior OS compared to other intrinsic subtypes (5-year OS rate, 92.2% vs. 75.6%; p=0.01).
Conclusion
A substantial portion of patients showed discrepancy between IHC subtype and PAM50 intrinsic subtype in our study. The survival analysis demonstrated that current IHC-based classification could mislead the treatment and result in poor outcome. Current guidelines for IHC might be updated accordingly.

Citations

Citations to this article as recorded by  
  • Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer
    Brenno Pastò, Riccardo Vida, Arianna Dri, Lorenzo Foffano, Serena Della Rossa, Lorenzo Gerratana, Fabio Puglisi
    The Breast.2025; 79: 103859.     CrossRef
  • Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
    Florencia P. Madorsky Rowdo, Rachel Martini, Sarah E. Ackermann, Colin P. Tang, Marvel Tranquille, Adriana Irizarry, Ilkay Us, Omar Alawa, Jenna E. Moyer, Michael Sigouros, John Nguyen, Majd Al Assaad, Esther Cheng, Paula S. Ginter, Jyothi Manohar, Brian
    Cancer Research.2025; 85(3): 551.     CrossRef
  • Defining the regulatory logic of breast cancer using single-cell epigenetic and transcriptome profiling
    Matthew J. Regner, Susana Garcia-Recio, Aatish Thennavan, Kamila Wisniewska, Raul Mendez-Giraldez, Brooke Felsheim, Philip M. Spanheimer, Joel S. Parker, Charles M. Perou, Hector L. Franco
    Cell Genomics.2025; 5(2): 100765.     CrossRef
  • PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study
    Judith Katharina Ballé, Martina Vetter, Tariku Wakuma Kenea, Pia Eber-Schulz, Christian Reibold, Hannes-Viktor Ziegenhorn, Kathrin Stückrath, Claudia Wickenhauser, Adamu Addissie, Pablo Santos, Eva Johanna Kantelhardt, Sefonias Getachew, Marcus Bauer
    BMC Cancer.2024;[Epub]     CrossRef
  • Migratory Tumor Cells Cooperate with Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer
    Eun Hye Joo, Sangmin Kim, Donghyun Park, Taeseob Lee, Woong-Yang Park, Kyung Yeon Han, Jeong Eon Lee
    International Journal of Molecular Sciences.2024; 25(11): 5876.     CrossRef
  • Discovery of a proliferation essential gene signature and actin‐like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple‐positive breast cancer
    Xiaofen Li, Shiping Luo, Wenfen Fu, Mingyao Huang, Xiewei Huang, Shaohong Kang, Jie Zhang, Qingshui Wang, Chuangui Song
    Cancer.2024; 130(S8): 1435.     CrossRef
  • Breast Cancer Molecular Subtyping in Practice: A Real-World Study of the APIS Breast Cancer Subtyping Assay in a Consecutive Series of Breast Core Biopsies
    Silvana Di Palma, Panagiotis Koliou, Alex Simonovic, Daniela Costa, Catherine Faulkes, Brenda Kobutungi, Felicity Paterson, Jonathan David Horsnell, Farrokh Pakzad, Tracey Irvine, Polly Partlett, Elizabeth Clayton, Nadine Collins
    International Journal of Molecular Sciences.2024; 25(5): 2616.     CrossRef
  • iCluF: an unsupervised iterative cluster-fusion method for patient stratification using multiomics data
    Sushil K Shakyawar, Balasrinivasa R Sajja, Jai Chand Patel, Chittibabu Guda, Marieke Kuijjer
    Bioinformatics Advances.2024;[Epub]     CrossRef
  • Differences in Histological Subtypes of Invasive Lobular Breast Carcinoma According to Immunohistochemical Molecular Classification
    Ivan Ilić, Jana Cvetković, Ratko Ilić, Ljubiša Cvetković, Aleksandar Milićević, Stefan Todorović, Pavle Ranđelović
    Diagnostics.2024; 14(6): 660.     CrossRef
  • Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study
    Tobias Berg, Maj-Britt Jensen, Alan Celik, Maj-Lis Talman, Maria Anna Misiakou, Ann Søegaard Knoop, Finn Cilius Nielsen, Bent Ejlertsen, Maria Rossing
    JCI Insight.2024;[Epub]     CrossRef
  • Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review
    Katerina S. Grechukhina, Daria A. Filonenko, Margarita V. Sukhova, Liudmila G. Zhukova
    Journal of Modern Oncology.2024; 26(2): 182.     CrossRef
  • Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study
    Ran Ran, Shidi Zhao, Yan Zhou, Xinyue Hang, Hui Wang, Yuan Fan, Yusi Zhang, Yifan Qiao, Jin Yang, Danfeng Dong
    BMC Cancer.2024;[Epub]     CrossRef
  • LUCAT1-Mediated Competing Endogenous RNA (ceRNA) Network in Triple-Negative Breast Cancer
    Deepak Verma, Sumit Siddharth, Ashutosh S. Yende, Qitong Wu, Dipali Sharma
    Cells.2024; 13(22): 1918.     CrossRef
  • Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data
    Kaiyuan Xing, Bo Zhang, Zixuan Wang, Yanru Zhang, Tengyue Chai, Jingkai Geng, Xuexue Qin, Xi Steven Chen, Xinxin Zhang, Chaohan Xu
    Cells.2023; 12(3): 367.     CrossRef
  • Moanna: Multi-Omics Autoencoder-Based Neural Network Algorithm for Predicting Breast Cancer Subtypes
    Richard Lupat, Rashindrie Perera, Sherene Loi, Jason Li
    IEEE Access.2023; 11: 10912.     CrossRef
  • Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer
    Thérèse Dix-Peek, Boitumelo P. Phakathi, Eunice J. van den Berg, Caroline Dickens, Tanya N. Augustine, Herbert Cubasch, Alfred I. Neugut, Judith S. Jacobson, Maureen Joffe, Paul Ruff, Raquel A. B. Duarte
    Breast Cancer Research and Treatment.2023; 199(1): 1.     CrossRef
  • A Simple Method for Robust and Accurate Intrinsic Subtyping of Breast Cancer
    Mehdi Hamaneh, Yi-Kuo Yu
    Cancer Informatics.2023;[Epub]     CrossRef
  • XAI-MethylMarker: Explainable AI approach for biomarker discovery for breast cancer subtype classification using methylation data
    Sheetal Rajpal, Ankit Rajpal, Arpita Saggar, Ashok K. Vaid, Virendra Kumar, Manoj Agarwal, Naveen Kumar
    Expert Systems with Applications.2023; 225: 120130.     CrossRef
  • XAI-CNVMarker: Explainable AI-based copy number variant biomarker discovery for breast cancer subtypes
    Sheetal Rajpal, Ankit Rajpal, Manoj Agarwal, Virendra Kumar, Ajith Abraham, Divya Khanna, Naveen Kumar
    Biomedical Signal Processing and Control.2023; 84: 104979.     CrossRef
  • The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity
    Vincenzo Salemme, Giorgia Centonze, Lidia Avalle, Dora Natalini, Alessio Piccolantonio, Pietro Arina, Alessandro Morellato, Ugo Ala, Daniela Taverna, Emilia Turco, Paola Defilippi
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
    Coralia Bueno Muiño, Miguel Martín, María del Monte-Millán, José Ángel García-Saénz, Sara López-Tarruella
    Cancers.2022; 14(3): 512.     CrossRef
  • Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
    Fanfan Li, Qian Ju, Cong Gao, Jingjing Li, Xiaolei Wang, Min Yan, Liying Zhang, Meiling Huang, Qihe Long, Xiangting Jin, Nanlin Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer
    Xinyu Ren, Yu Song, Yanna zhang, Huanwen Wu, Longyun Chen, Junyi Pang, Liangrui Zhou, Songjie Shen, Zhiyong Liang
    BMC Cancer.2022;[Epub]     CrossRef
  • Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting
    Ramona Erber, Miriam Angeloni, Robert Stöhr, Michael P. Lux, Daniel Ulbrich-Gebauer, Enrico Pelz, Agnes Bankfalvi, Kurt W. Schmid, Robert F. H. Walter, Martina Vetter, Christoph Thomssen, Doris Mayr, Frederick Klauschen, Peter Sinn, Karl Sotlar, Katharina
    International Journal of Molecular Sciences.2022; 23(15): 8716.     CrossRef
  • The Current Staging and Classification Systems of Breast Cancer and Their Pitfalls: Is It Possible to Integrate the Complexity of this Neoplasm into a Unified Staging System?
    Felipe Andrés Cordero da Luz, Breno Jeha Araújo, Rogério Agenor de Araújo
    Critical Reviews in Oncology/Hematology.2022; : 103781.     CrossRef
  • Prognostic factors and molecular subtypes in young women with breast cancer
    Yasmin Shukair, Rafaela Veiga Monteiro
    Mastology.2022;[Epub]     CrossRef
  • Understanding Breast Cancers through Spatial and High-Resolution Visualization Using Imaging Technologies
    Haruko Takahashi, Daisuke Kawahara, Yutaka Kikuchi
    Cancers.2022; 14(17): 4080.     CrossRef
  • Risk Stratification for Breast Cancer Patient by Simultaneous Learning of Molecular Subtype and Survival Outcome Using Genetic Algorithm-Based Gene Set Selection
    Bonil Koo, Dohoon Lee, Sangseon Lee, Inyoung Sung, Sun Kim, Sunho Lee
    Cancers.2022; 14(17): 4120.     CrossRef
  • Detecting the expression of HRs and BCL2 via IHC can help identify luminal A-like subtypes of triple-positive breast cancers
    Yingying Xu, Yonghao Liang, Guanghao Yin
    Clinical and Translational Oncology.2022; 25(4): 1024.     CrossRef
  • Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
    Marcela Carausu, Matthieu Carton, Véronique Diéras, Thierry Petit, Séverine Guiu, Anthony Gonçalves, Paule Augereau, Jean Marc Ferrero, Christelle Levy, Mony Ung, Isabelle Desmoulins, Marc Debled, Thomas Bachelot, Barbara Pistilli, Jean-Sébastien Frenel,
    JAMA Network Open.2022; 5(12): e2247154.     CrossRef
  • Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review
    Ran Ran, Yingying Ma, Hui Wang, Jin Yang, Jiao Yang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study
    Lin Wang, Qian Li, Vasily N. Aushev, Alfred I. Neugut, Regina M. Santella, Susan Teitelbaum, Jia Chen
    Breast Cancer.2021; 28(6): 1235.     CrossRef
  • Triphasic DeepBRCA-A Deep Learning-Based Framework for Identification of Biomarkers for Breast Cancer Stratification
    Sheetal Rajpal, Manoj Agarwal, Virendra Kumar, Anamika Gupta, Naveen Kumar
    IEEE Access.2021; 9: 103347.     CrossRef
  • Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level
    Yan Zhang, Denan Zhang, Qingkang Meng, Ziqi Liu, Hongbo Xie, Lei Liu, Fei Xu, Xiujie Chen
    BMC Cancer.2021;[Epub]     CrossRef
  • A single-cell and spatially resolved atlas of human breast cancers
    Sunny Z. Wu, Ghamdan Al-Eryani, Daniel Lee Roden, Simon Junankar, Kate Harvey, Alma Andersson, Aatish Thennavan, Chenfei Wang, James R. Torpy, Nenad Bartonicek, Taopeng Wang, Ludvig Larsson, Dominik Kaczorowski, Neil I. Weisenfeld, Cedric R. Uytingco, Jen
    Nature Genetics.2021; 53(9): 1334.     CrossRef
  • Improving Prognosis of Surrogate Assay for Breast Cancer Patients by Absolute Quantitation of Ki67 Protein Levels Using Quantitative Dot Blot (QDB) Method
    Junmei Hao, Yan Lyu, Jiarui Zou, Yunyun Zhang, Shuishan Xie, Lili Jing, Fangrong Tang, Jiahong Lyu, Wenfeng Zhang, Jianbo Zhang, Xunting Wang, Kuisheng Chen, Jiandi Zhang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma
    Danhui Zhao, Xin Fu, Joseph Rohr, Yingmei Wang, Mingyang Li, Xiuming Zhang, Junhui Qin, Mengwei Xu, Chao Li, Guorui Sun, Zhe Wang, Shuangping Guo
    Pathology - Research and Practice.2021; 228: 153677.     CrossRef
  • Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets
    Stefania Morganti, Giuseppe Curigliano
    Expert Review of Precision Medicine and Drug Development.2020; 5(1): 7.     CrossRef
  • MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes
    Elise Klæstad, Signe Opdahl, Monica Jernberg Engstrøm, Borgny Ytterhus, Elisabeth Wik, Anna Mary Bofin, Marit Valla
    Breast Cancer Research and Treatment.2020; 180(1): 73.     CrossRef
  • Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Liuwen Yu, Fangmeng Fu, Jing Li, Meng Huang, Bangwei Zeng, Yuxiang Lin, Qian Mei, Jinxing Lv, Chuan Wang
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Hormone Receptor-Status Prediction in Breast Cancer Using Gene Expression Profiles and Their Macroscopic Landscape
    Seokhyun Yoon, Hye Sung Won, Keunsoo Kang, Kexin Qiu, Woong June Park, Yoon Ho Ko
    Cancers.2020; 12(5): 1165.     CrossRef
  • Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
    Jing Yu, Jiayi Wu, Ou Huang, Jianrong He, Zhu Li, Weiguo Chen, Yafen Li, Xiaosong Chen, Kunwei Shen
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • DGM-CM6: A New Model to Predict Distant Recurrence Risk in Operable Endocrine-Responsive Breast Cancer
    Lei Lei, Xiao-Jia Wang, Yin-Yuan Mo, Skye Hung-Chun Cheng, Yunyun Zhou
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Subtype-specific risk models for accurately predicting the prognosis of breast cancer using differentially expressed autophagy-related genes
    Baoai Han, He Zhang, Yuying Zhu, Xingxing Han, Zhiyong Wang, Zicong Gao, Yue Yuan, Ruinan Tian, Fei Zhang, Ruifang Niu
    Aging.2020; 12(13): 13318.     CrossRef
  • Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
    Ji-Yeon Kim, Kyunghee Park, Seock-Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park
    Breast Cancer Research and Treatment.2020; 184(3): 743.     CrossRef
  • Quantification of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Protein Expression in Bone Biopsies by Targeted Mass Spectrometry without Acid Decalcification
    Regine M Schoenherr, Uliana J Voytovich, Jeffrey R Whiteaker, Vijayakrishna K Gadi, Julie R Gralow, Amanda G Paulovich
    Clinical Chemistry.2020; 66(11): 1459.     CrossRef
  • A Topic Modeling Analysis of TCGA Breast and Lung Cancer Transcriptomic Data
    Filippo Valle, Matteo Osella, Michele Caselle
    Cancers.2020; 12(12): 3799.     CrossRef
  • Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease
    Giuseppe Viale, Elisabetta Munzone
    The Breast.2019; 48: S49.     CrossRef
  • 13,506 View
  • 480 Download
  • 50 Web of Science
  • 48 Crossref
Close layer
Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data
Eun Kyoung Kim, Jinhyun Cho, Ji-Yeon Kim, Sung-A Chang, Sung-Ji Park, Jin Oh Choi, Sang Chol Lee, Jin Seok Ahn, Seung Woo Park, Young-Hyuck Im, Eun Seok Jeon, Yeon Hee Park
Cancer Res Treat. 2019;51(2):727-736.   Published online September 4, 2018
DOI: https://doi.org/10.4143/crt.2018.262
AbstractAbstract PDFPubReaderePub
Purpose
While concerns regarding trastuzumab-related cardiac dysfunction (TRCD) in patients with breast cancer are increasing, there is a lack of evidence supporting the current recommendations for TRCD monitoring. We aimed to investigate the clinical predictors of TRCD in the adjuvant setting of human epidermal growth factor receptor 2–positive breast cancer patients.
Materials and Methods
From August 2003 to April 2016, consecutive 998 patients who were treated with adjuvant trastuzumab for breast cancer were retrospectively evaluated. TRCD was defined as a decrease ≥10% in left ventricular ejection fraction (LVEF), with a decline below the normal limit or symptomatic heart failure.
Results
Among 787 eligible patients who had complete data sets consisting of both baseline and follow-up assessment of left ventricular systolic function by echocardiography (mean age, 49.9±9.5 years), 58 (7.4%) developed TRCD. TRCD patients had lower baseline LVEF (63% [59–66] vs. 65% [61–68], p=0.016) and more frequently administered Adriamycin (98% vs. 89%, p=0.022) than those without TRCD. On follow-up echocardiography, a drop in LVEF ≥5% within the first 3 months was more frequent in TRCD patients (78.3% vs. 38.4%, p<0.001). Regardless of baseline LVEF and Adriamycin treatment, a drop in LVEF ≥5% within the first 3 months of trastuzumab administration was strongly associated with the development of TRCD (adjusted hazard ratio, 45.1[17.0–127.6], p<0.001).
Conclusion
The overall incidence of TRCD was 7.4% in Asian breast cancer patients treated with adjuvant trastuzumab. A decline in LVEF ≥5% within the first 3 months of trastuzumab initiation was strongly associated with TRCD development in patients with breast cancer.

Citations

Citations to this article as recorded by  
  • Noninvasive identification and therapeutic implications of supernormal left ventricular contractile phenotype
    Yi Wang, Lixue Yin
    Exploration of Cardiology.2024; 2(3): 97.     CrossRef
  • Significant Influence of Cardiac Radiation Dose on the Risk of Cardiotoxicity in Patients Receiving Adjuvant Trastuzumab and Radiation Therapy for Breast Cancer
    Tae Hoon Lee, Nalee Kim, Eun Kyoung Kim, Jin Seok Ahn, Yeon Hee Park, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Won Kyung Cho, Won Park, Tae Gyu Kim, Jee Suk Chang, Haeyoung Kim
    International Journal of Radiation Oncology*Biology*Physics.2024;[Epub]     CrossRef
  • ABSDELL Model: Development and Internal Validation of a Risk Prediction Model of LVEF Decline in Breast Cancer Patients Treated With Trastuzumab
    Xin Liu, Liyuan Tao, Mopei Wang, Haiyan Li, Weixian Xu
    Clinical Breast Cancer.2023; 23(1): 23.     CrossRef
  • New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review
    Alexia Alexandraki, Elisavet Papageorgiou, Marina Zacharia, Kalliopi Keramida, Andri Papakonstantinou, Carlo M. Cipolla, Dorothea Tsekoura, Katerina Naka, Ketti Mazzocco, Davide Mauri, Manolis Tsiknakis, Georgios C. Manikis, Kostas Marias, Yiola Marcou, E
    Cancers.2023; 15(13): 3290.     CrossRef
  • Guidelines in Cardio-Oncology: The Balance Between Evidence and Expert Opinion
    Douglas J. Leedy, Marta Alhama-Belotto, William R. Gwin, Ruchi Kapoor, Elina Minami, Eric J. Chow, Richard K. Cheng
    Current Treatment Options in Cardiovascular Medicine.2023; 25(11): 639.     CrossRef
  • Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system
    Abdulrazaq S. Al-Jazairi, Nahlah Bahammam, Dhai Aljuaid, Lama Almutairi, Shroog Alshahrani, Norah Albuhairan, Peter M. B. Cahusac, Ghazwa B. Korayem
    Cardio-Oncology.2023;[Epub]     CrossRef
  • Lessons learnt in the first year of an Australian pediatric cardio oncology clinic
    Claudia Toro, Ben Felmingham, Mangesh Jhadav, David S. Celermajer, Andre La Gerche, John O’Sullivan, Sanjeev Kumar, Marion K. Mateos, Joy Fulbright, Dinisha Govender, Lane Collier, Michael Cheung, David D. Eisenstat, Peter W. Lange, Julian Ayer, David A.
    Cardio-Oncology.2023;[Epub]     CrossRef
  • Deceleration capacity of heart rate predicts trastuzumab‐related cardiotoxicity in patients with HER2‐positive breast cancer: A prospective observational study
    Yanying Feng, Zhenhua Qin, Zhijun Yang
    Journal of Clinical Pharmacy and Therapeutics.2021; 46(1): 93.     CrossRef
  • Vascular and Cardiac Prognostic Determinants in Patients with Gynecological Cancers: A Six-Year Follow-up Study
    Pietro Scicchitano, Marco Tucci, Gabriella Ricci, Michele Gesualdo, Santa Carbonara, Giuseppe Totaro, Annagrazia Cecere, Rosa Carbonara, Francesca Cortese, Vera Loizzi, Gennaro Cormio, Ettore Cicinelli, Marco Matteo Ciccone
    Applied Sciences.2021; 11(13): 6091.     CrossRef
  • Cardiotoxicity Associated with Chemotherapy Used in Gastrointestinal Tumours
    Liliana Maria Radulescu, Dan Radulescu, Tudor-Eliade Ciuleanu, Dana Crisan, Elena Buzdugan, Dragos-Mihai Romitan, Anca Dana Buzoianu
    Medicina.2021; 57(8): 806.     CrossRef
  • Successful Use of Digoxin for Trastuzumab-related Cardiotoxicity to Facilitate Breast Surgery in a Patient with Metastatic Breast Cancer
    Tsuyoshi SHIGA, Takako KAMIO, Kenta UTO, Kotaro ARAI
    Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics .2021; 52(4): 101.     CrossRef
  • Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study
    Elena Geuna, Pasquale Lombardi, Rossella Martinello, Davide Garino, Alessandro Bonzano, Danilo Galizia, Annamaria Nuzzo, Paola Berchialla, Paolo Becco, Monica Mangioni, Lorena De Zarlo, Filippo Montemurro
    Cancers.2020; 12(2): 327.     CrossRef
  • A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer
    Wala Ben Kridis, Syrine Sghaier, Salma Charfeddine, Nabil Toumi, Jamel Daoud, Samir Kammoun, Afef Khanfir
    American Journal of Clinical Oncology.2020; 43(7): 510.     CrossRef
  • Examining Cardiotoxicity With HER2 Therapies
    Neelima Denduluri
    JACC: CardioOncology.2020; 2(2): 176.     CrossRef
  • Determinants of left ventricular ejection fraction and a novel method to improve its assessment of myocardial contractility
    Manuel Ignacio Monge García, Zhongping Jian, Jos J. Settels, Charles Hunley, Maurizio Cecconi, Feras Hatib, Michael R. Pinsky
    Annals of Intensive Care.2019;[Epub]     CrossRef
  • The Role of Echocardiography in Cardio-oncology Patients: Contemporary Indications and Future Directions
    Saiuj Bhat, Nestor Gahungu, Paaladinesh Thavendiranathan, Girish Dwivedi
    Current Cardiovascular Imaging Reports.2019;[Epub]     CrossRef
  • Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)
    Zhuyu Xu, Dandan Guo, Zhongliang Jiang, Rongsheng Tong, Peidu Jiang, Lan Bai, Lu Chen, Yuxuan Zhu, Chun Guo, Jianyou Shi, Dongke Yu
    European Journal of Medicinal Chemistry.2019; 183: 111682.     CrossRef
  • 10,051 View
  • 262 Download
  • 16 Web of Science
  • 17 Crossref
Close layer
Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea
Hee Kyung Kim, Jun Soo Ham, Seonggyu Byeon, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, Jinhyun Cho, Ji Yun Lee, Sung Hee Lim, Hae Su Kim, Ji-Yeon Kim, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Se Kyung Lee, Soo Youn Bae, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2016;48(4):1382-1388.   Published online March 11, 2016
DOI: https://doi.org/10.4143/crt.2015.423
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to assess the tumor characteristics and long-term clinical outcomes of adjuvant treatments after surgery with a curative aim for patients with breast cancer who are 65 years and older. Materials and Methods Patients with breast cancer who underwent curative surgery from 2000 to 2009 were analyzed (n=4,388). Tumor characteristics and survival outcome were compared by dividing the patients into two age groups (< 65 and ≥ 65 years old). The Kaplan-Meier method was used for comparison of survival rates by log-rank test, and a Cox regression model was used to examine the effect of variables.
Results
Among 4,388 patients with invasive breast cancer, 317 patients (7.2%) were 65 years or older and the median age of all patients was 47 years (range, 18 to 91 years). Tumor characteristics were similar between the two age groups, but the older patients were treated less often with adjuvant treatments. During a median follow-up period of 122 months, recurrence-free survival (RFS) was equivalent for patients 65 years and older compared to younger patients, but significantly worse in overall survival (OS) and breast cancer–specific survival (BCSS) (5-year OS, 94.3% vs. 90.5%; p < 0.001 and 5-year BCSS, 94.7% vs. 91.8%; p=0.031). In the multivariate model, age ≥ 65 years old was identified as an independent risk factor for OS and RFS. Conclusion Elderly breast cancer appeared to have worse outcomes with very low prevalence in Korea, despite similar tumor characteristics. More active adjuvant therapies would have a role for aggressive subtypes for fit, elderly patients.

Citations

Citations to this article as recorded by  
  • HISTOPATHOLOGICAL AND BIOLOGICAL BEHAVIOR OF BREAST CANCER IN ELDERLY KURDISH WOMEN
    Kamal Saeed, Shewaz Salih
    JOURNAL OF SULAIMANI MEDICAL COLLEGE.2023; 13(4): 11.     CrossRef
  • Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry
    Junyup Kim, Seri Hong, Jae Jun Lee, Young-Joo Won, Eun Sook Lee, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Eun-Gyeong Lee, Heein Jo, Hyun Hee Kim, So-Youn Jung
    Breast Cancer Research and Treatment.2021; 187(3): 785.     CrossRef
  • Survival outcomes in elderly Taiwanese women according to breast cancer subtype and lymph node status: A single-center retrospective study
    Kung-Hung Lin, Huan-Ming Hsu, Kuo-Feng Hsu, Chi-Hong Chu, Zhi-Jie Hong, Chun-Yu Fu, Yu-Ching Chou, Golshan Mehra, Ming-Shen Dai, Jyh-Cherng Yu, Guo-Shiou Liao, Jason Chia-Hsun Hsieh
    PLOS ONE.2021; 16(12): e0261258.     CrossRef
  • Could lymph node evaluation be eliminated in nearly 50% of women with early stage ER/PR positive breast cancer?
    Juan Ruiz, Gerson Maldonado, Elizabeth Ablah, Hayrettin Okut, Jared Reyes, Karson Quinn, Patty L. Tenofsky
    The American Journal of Surgery.2020; 220(6): 1417.     CrossRef
  • Overall survival of elderly patients with breast cancer is not related to breast-cancer specific survival: A single institution experience in Japan
    Haruko Takuwa, Wakako Tsuji, Fumiaki Yotsumoto
    Breast Disease.2018; 37(4): 177.     CrossRef
  • Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting
    Chiara Mandoj, Laura Pizzuti, Domenico Sergi, Isabella Sperduti, Marco Mazzotta, Luigi Di Lauro, Antonella Amodio, Silvia Carpano, Anna Di Benedetto, Claudio Botti, Francesca Ferranti, Anna Antenucci, Maria Gabriella D’Alessandro, Paolo Marchetti, Silveri
    Journal of Translational Medicine.2018;[Epub]     CrossRef
  • Do site and type of metastasis in breast cancer show a changing pattern with increased age? A cross comparison of clinicopathological characteristics between age groups
    Majid Akrami, Afrooz Sepahdar, Peyman Arasteh, Sedigheh Tahmasebi, Vahid Zangouri, Azam Askari, Babak Pezeshki, Abdolrasoul Talei
    World Journal of Surgical Oncology.2018;[Epub]     CrossRef
  • Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice
    Jessemae L. Welsh, Tanya L. Hoskin, Courtney N. Day, Elizabeth B. Habermann, Matthew P. Goetz, Judy C. Boughey
    Annals of Surgical Oncology.2017; 24(10): 2881.     CrossRef
  • Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer
    Qixing Tan, Qinghong Qin, Weiping Yang, Bin Lian, Qinguo Mo, Changyuan Wei
    Medicine.2016; 95(44): e5302.     CrossRef
  • 12,673 View
  • 156 Download
  • 8 Web of Science
  • 9 Crossref
Close layer
Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
Ji-Yeon Kim, Kyunghee Park, Hae Hyun Jung, Eunjin Lee, Eun Yoon Cho, Kwang Hee Lee, Soo Youn Bae, Se Kyung Lee, Seok Won Kim, Jeong Eon Lee, Seok Jin Nam, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2016;48(4):1338-1350.   Published online February 18, 2016
DOI: https://doi.org/10.4143/crt.2015.430
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
TP53, the most frequently mutated gene in breast cancer, is more frequently altered in HER2-enriched and basal-like breast cancer. However, no studies have clarified the role of TP53 status as a prognostic and predictive marker of triple-negative breast cancer (TNBC).
Materials and Methods
We performed p53 immunohistochemistry (IHC), nCounter mRNA expression assay, and DNA sequencing to determine the relationship between TP53 alteration and clinical outcomes of TNBC patients.
Results
Seventy-seven of 174 TNBC patients were found to harbor a TP53 mutation. Patients with missense mutations showed high protein expression in contrast to patients with deletion mutations (positivity of IHC: wild type vs. missense vs. deletion mutation, 53.6% vs. 89.8% vs. 25.0%, respectively; p < 0.001). TP53 mRNA expression was influenced by mutation status (mRNA expression [median]: wild type vs. missense vs. deletion mutation, 207.36± 132.73 vs. 339.61±143.21 vs. 99.53±99.57,respectively; p < 0.001). According to survival analysis, neither class of mutation nor protein or mRNA expression status had any impact on patient prognosis. In subgroup analysis, low mRNA expression was associated with poor prognosis in patientswith a TP53 missense mutation (5-year distantrecurrence-free survival [5Y DRFS]: low vs. high, 50.0% vs. 87.8%; p=0.009), while high mRNA expression with a TP53 deletion mutation indicated poor prognosis (5Y DRFS: low vs. high, 91.7% vs. 75.0%; p=0.316).
Conclusion
Association between TP53 mutation and expression indicates a potential prognostic marker of TNBC; hence both DNA sequencing and mRNA expression analysis may be required to predict the prognosis of TNBC patients.

Citations

Citations to this article as recorded by  
  • Immunohistochemical Characterization of a Large Cohort of Triple Negative Breast Cancer
    Rachel Han, Sharon Nofech-Mozes, Dina Boles, Hannah Wu, Nikolina Curcin, Elzbieta Slodkowska
    International Journal of Surgical Pathology.2024; 32(2): 239.     CrossRef
  • Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice
    Laura Lopez-Gonzalez, Alicia Sanchez Cendra, Cristina Sanchez Cendra, Eduardo David Roberts Cervantes, Javier Cassinello Espinosa, Tatiana Pekarek, Oscar Fraile-Martinez, Cielo García-Montero, Ana María Rodriguez-Slocker, Laura Jiménez-Álvarez, Luis G. Gu
    Medicina.2024; 60(1): 168.     CrossRef
  • TP53R175H mutation promotes breast cancer cell proliferation through CORO1A–P38 MAPK pathway regulation
    Yali Su, Jiaxuan Zhao, Haoran Fu, Zeliang Liu, Panyan Du, Jianxia Zheng, Jinghua Wu, Jinghua Zhang
    Biochemical Pharmacology.2024; 221: 116047.     CrossRef
  • TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer
    Akiko Arimura, Kazuko Sakai, Kazuhisa Kaneshiro, Takafumi Morisaki, Saori Hayashi, Kimihisa Mizoguchi, Mai Yamada, Masaya Kai, Mayumi Ono, Kazuto Nishio, Masafumi Nakamura, Makoto Kubo
    Cancers.2024; 16(6): 1184.     CrossRef
  • Exploration of newly synthesized deferasirox derivatives as potential anti-cancer agents via in-vitro and in-silico approaches
    Muhammad Zahid Ullah, Zahid Hussain, Syed Ahmad Shakir, Mahnoor Mahmood, Syeda Abida Ejaz, Mubashir Aziz, Ammara Fayyaz, Jamshed Iqbal, Amara Mumtaz
    International Journal of Biological Macromolecules.2024; 283: 137971.     CrossRef
  • Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
    Zhijun Li, Yiqun Han, Jiayu Wang, Binghe Xu
    Journal of Personalized Medicine.2023; 13(2): 190.     CrossRef
  • The role of p53 and ki67 in predicting clinical outcome in breast cancer patients
    Bhanu Prakash Lalkota, B.J Srinivasa, Mani V. Swamy, Diganta Hazarika, B.M Jeet, K Jyothi, Mithua Ghosh, Suhail M. Sayeed, Mohammad Nasiruddin, Radheshyam Naik
    Journal of Cancer Research and Therapeutics.2023; 19(2): 208.     CrossRef
  • Novel microtubule inhibitor SQ overcomes multidrug resistance in MCF-7/ADR cells by inhibiting BCRP function and mediating apoptosis
    Xing Chang, Zi Liu, Simeng Cao, Jiang Bian, Dayong Zheng, Nuo Wang, Qi Guan, Yingliang Wu, Weige Zhang, Zengqiang Li, Daiying Zuo
    Toxicology and Applied Pharmacology.2022; 436: 115883.     CrossRef
  • Targeted gene next‐generation sequencing reveals genomic profile in a cohort of 46 Chinese patients with breast cancer
    Jie Yao, Qian Chen, Jun‐qi Zhu, Rui‐gang Cai
    The Journal of Gene Medicine.2022;[Epub]     CrossRef
  • Effect of the elastin-derived peptides (VGVAPG and VVGPGA) on breast (MCF-7) and lung (A549) cancer cell lines in vitro
    Konrad A. Szychowski, Bartosz Skóra, Tadeusz Pomianek
    Biomedicine & Pharmacotherapy.2022; 151: 113149.     CrossRef
  • p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer
    Ai-Yan Xing, Long Liu, Ke Liang, Bin Wang
    Cancer Investigation.2022; 40(10): 879.     CrossRef
  • Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer
    Hyo-Jin Kim, Bo-Gyeong Seo, Eun-Chan Seo, Kwang-Min Lee, Cheol Hwangbo
    Current Issues in Molecular Biology.2022; 44(12): 5848.     CrossRef
  • An integrative pan-cancer analysis of COPB1 based on data mining
    Heyan Chen, Kunlong Li, Yijun Li, Peilin Xie, Jianjun He, Huimin Zhang
    Cancer Biomarkers.2021; 30(1): 13.     CrossRef
  • Sex differences in expression of immune elements emerge in children, young adults and mice with osteosarcoma
    Lauren J. Mills, Logan G. Spector, David A. Largaespada, Lindsay A. Williams
    Biology of Sex Differences.2021;[Epub]     CrossRef
  • GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature
    Patrizia Querzoli, Massimo Pedriali, Rosa Rinaldi, Paola Secchiero, Paolo Giorgi Rossi, Elisabetta Kuhn
    Diagnostics.2021; 11(4): 604.     CrossRef
  • Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis
    Dharambir Kashyap, Vivek Kumar Garg, Elise N. Sandberg, Neelam Goel, Anupam Bishayee
    Pharmaceutics.2021; 13(4): 569.     CrossRef
  • Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer
    Weikai Xiao, Guochun Zhang, Bo Chen, Xiaoqing Chen, Lingzhu Wen, Jianguo Lai, Xuerui Li, Min Li, Hao Liu, Jing Liu, Han Han-Zhang, Analyn Lizaso, Ning Liao
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Syndrome de Peutz–Jeghers et surveillance mammaire : les nouvelles recommandations à propos d’une observation
    M. Osada, P. Maniez, N. Taris, C. Mathelin
    Gynécologie Obstétrique Fertilité & Sénologie .2021; 49(10): 795.     CrossRef
  • Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer
    Reyhaneh Farghadani, Rakesh Naidu
    Cancers.2021; 13(14): 3427.     CrossRef
  • Effect of Dickkopf-1 (Dkk-1) and SP600125, a JNK Inhibitor, on Wnt Signaling in Canine Prostate Cancer Growth and Bone Metastases
    Wachiraphan Supsavhad, Bardes B. Hassan, Jessica K. Simmons, Wessel P. Dirksen, Said M. Elshafae, Nicole A. Kohart, Aylin A. Demirer, Thomas J. Rosol
    Veterinary Sciences.2021; 8(8): 153.     CrossRef
  • TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines
    Ashkan Shahbandi, Hoang D. Nguyen, James G. Jackson
    Trends in Cancer.2020; 6(2): 98.     CrossRef
  • The novel TP53 3′-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection
    Feng Zeng, Jianfu Heng, Xinwu Guo, Yue Wang, Wenhan Wu, Lili Tang, Min Chen, Shouman Wang, Hongyu Deng, Jun Wang
    Breast Cancer Research and Treatment.2020; 180(1): 237.     CrossRef
  • Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China
    Zongbi Yi, Fei Ma, Guohua Rong, Yanfang Guan, Chunxiao Li, Binghe Xu
    Cancer Communications.2020; 40(6): 260.     CrossRef
  • Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer
    Gu Xiao, Devon Lundine, George K. Annor, Jorge Canar, Viola Ellison, Alla Polotskaia, Patrick L. Donabedian, Thomas Reiner, Galina F. Khramtsova, Olufunmilayo I. Olopade, Alexander Mazo, Jill Bargonetti
    Cancer Research.2020; 80(3): 394.     CrossRef
  • Genomic analysis of racial differences in triple negative breast cancer
    Chang-Sheng Chang, Eiko Kitamura, Joan Johnson, Roni Bollag, Lesleyann Hawthorn
    Genomics.2019; 111(6): 1529.     CrossRef
  • p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy
    Hyeon Jeong Oh, Jeong Mo Bae, Xianyu Wen, Seorin Jung, Younghoon Kim, Kyung Ju Kim, Nam-Yun Cho, Jung Ho Kim, Sae-Won Han, Tae-You Kim, Gyeong Hoon Kang
    British Journal of Cancer.2019; 120(8): 797.     CrossRef
  • Immunostaining for p53 and p16CDKN2A Protein Is Not Predictive of Prognosis for Dogs with Malignant Mammary Gland Neoplasms
    John S Munday, Harsha Ariyarathna, Danielle Aberdein, Neroli A Thomson
    Veterinary Sciences.2019; 6(1): 34.     CrossRef
  • NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
    Paul B. Mullan, Victoria Bingham, Paula Haddock, Gareth W. Irwin, Elaine Kay, Stephen McQuaid, Niamh E. Buckley
    BMC Cancer.2019;[Epub]     CrossRef
  • Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma
    Jing-ping Li, Xiang-mei Zhang, Zhenzhen Zhang, Li-hua Zheng, Sonali Jindal, Yun-jiang Liu
    Medicine.2019; 98(18): e15449.     CrossRef
  • Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis
    Fabiola Giudici, Elisabetta Petracci, Oriana Nanni, Cristina Bottin, Maurizio Pinamonti, Fabrizio Zanconati, Bruna Scaggiante, Aamir Ahmad
    PLOS ONE.2019; 14(6): e0218030.     CrossRef
  • Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00
    Elisabetta Munzone, Kathryn P. Gray, Caterina Fumagalli, Elena Guerini-Rocco, István Láng, Thomas Ruhstaller, Lorenzo Gianni, Roswitha Kammler, Giuseppe Viale, Angelo Di Leo, Alan S. Coates, Richard D. Gelber, Meredith M. Regan, Aron Goldhirsch, Massimo B
    Breast Cancer Research and Treatment.2018; 170(2): 351.     CrossRef
  • Cold atmospheric plasma conveys selectivity on triple negative breast cancer cells both in vitro and in vivo
    Liangjian Xiang, Xiaoyu Xu, Shuo Zhang, Dongyan Cai, Xiaofeng Dai
    Free Radical Biology and Medicine.2018; 124: 205.     CrossRef
  • Genetic Markers in Triple-Negative Breast Cancer
    Zuzana Sporikova, Vladimira Koudelakova, Radek Trojanec, Marian Hajduch
    Clinical Breast Cancer.2018; 18(5): e841.     CrossRef
  • Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy‐treated triple negative breast cancer
    Soo Youn Bae, Seung Pil Jung, Se Kyung Lee, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam
    The Kaohsiung Journal of Medical Sciences.2018; 34(12): 663.     CrossRef
  • Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer
    Yanli Luo, Wentao Huang, Huizhen Zhang, Guang Liu
    Oncology Letters.2018;[Epub]     CrossRef
  • P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients
    Yunbao Pan, Yufen Yuan, Guoshi Liu, Yongchang Wei, William B. Coleman
    PLOS ONE.2017; 12(2): e0172324.     CrossRef
  • Alcohol promotes migration and invasion of triple‐negative breast cancer cells through activation of p38 MAPK and JNK
    Ming Zhao, Erin W. Howard, Amanda B. Parris, Zhiying Guo, Qingxia Zhao, Xiaohe Yang
    Molecular Carcinogenesis.2017; 56(3): 849.     CrossRef
  • Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis
    Zongbi Yi, Fei Ma, Chunxiao Li, Rongrong Chen, Lifang Yuan, Xiaoying Sun, Xiuwen Guan, Lixi Li, Binliang Liu, Yanfang Guan, Haili Qian, Binghe Xu
    Scientific Reports.2017;[Epub]     CrossRef
  • TP53 gene expression levels and tumor aggressiveness in canine mammary carcinomas
    Táya F. Oliveira, Tábata Maués, Mariana S. Ramundo, Agnes Marie S. Figueiredo, Marcela F. V. de Mello, Kênia B. El-Jaick, Maria de Lourdes G. Ferreira, Ana Maria R. Ferreira
    Journal of Veterinary Diagnostic Investigation.2017; 29(6): 865.     CrossRef
  • Overexpression of p53 protein is a marker of poor prognosis in Mexican women with breast cancer
    Jisela Dimas-González, Vilma Maldonado-Lagunas, José Díaz-Chávez, María Eugenia López-Arellano, José Muñoz-Camacho, Marco Antonio Terán-Porcayo, Alfredo Lagunas-Martínez
    Oncology Reports.2017; 37(5): 3026.     CrossRef
  • Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing
    Xi-Xi Chen, Qian Zhong, Yang Liu, Shu-Mei Yan, Zhang-Hua Chen, Shan-Zhao Jin, Tian-Liang Xia, Ruo-Yan Li, Ai-Jun Zhou, Zhe Su, Yu-Hua Huang, Qi-Tao Huang, Li-Yun Huang, Xing Zhang, Yan-Na Zhao, Jin-Ping Yun, Qiu-Liang Wu, Dong-Xin Lin, Fan Bai, Mu-Sheng Z
    Nature Communications.2017;[Epub]     CrossRef
  • Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
    Ji-Yeon Kim, Eunjin Lee, Kyunghee Park, Woong-Yang Park, Hae Hyun Jung, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
    Oncotarget.2017; 8(17): 27997.     CrossRef
  • miR-34a expression in human breast cancer is associated with drug resistance
    Zhi-Hua Li, Xueling Weng, Qiu-Yun Xiong, Jian-Hong Tu, An Xiao, Wei Qiu, Yu Gong, Er-Wei Hu, Songyin Huang, Ya-Li Cao
    Oncotarget.2017; 8(63): 106270.     CrossRef
  • Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer
    Min Chong Kim, Jung Eun Choi, Soo Jung Lee, Young Kyung Bae
    Annals of Surgical Oncology.2016; 23(11): 3524.     CrossRef
  • 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway
    Jingwen Xu, Mengting Han, Jiwei Shen, Qi Guan, Zhaoshi Bai, Binyue Lang, Huijuan Zhang, Zengqiang Li, Daiying Zuo, Weige Zhang, Yingliang Wu
    Cancer Letters.2016; 383(1): 9.     CrossRef
  • 17,368 View
  • 336 Download
  • 52 Web of Science
  • 45 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP